Ubrogepant Patent Expiration

Ubrogepant is Used for the acute treatment of migraines in adults with or without aura, including those with severe hepatic or renal impairment. It was first introduced by Abbvie Inc in its drug Ubrelvy on Dec 23, 2019.


Ubrogepant Patents

Given below is the list of patents protecting Ubrogepant, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Ubrelvy US11717515 Treatment of migraine Dec 22, 2041 Abbvie
Ubrelvy US11857542 Treatment of migraine Dec 22, 2041 Abbvie
Ubrelvy US12070450 Treatment of migraine Dec 22, 2041 Abbvie
Ubrelvy US10117836 Tablet formulation for CGRP active compounds Jan 30, 2035 Abbvie
Ubrelvy US11925709 Tablet formulation for CGRP active compounds Jan 30, 2035 Abbvie
Ubrelvy US8912210 Piperidinone carboxamide azaindane CGRP receptor antagonists Dec 23, 2033 Abbvie
Ubrelvy US8754096 Piperidinone carboxamide azaindane CGRP receptor antagonists Jul 19, 2032 Abbvie
Ubrelvy US9499545 Piperidinone carboxamide azaindane CGRP receptor antagonists Nov 10, 2031 Abbvie
Ubrelvy US9833448 Piperidinone carboxamide azaindane CGRP receptor antagonists Nov 10, 2031 Abbvie



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ubrogepant's patents.

Given below is the list recent legal activities going on the following patents of Ubrogepant.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 11 Apr, 2024 US9499545
Patent Issue Date Used in PTA Calculation 12 Mar, 2024 US11925709
Email Notification 22 Feb, 2024 US11925709
Issue Notification Mailed 21 Feb, 2024 US11925709
transaction for FDA Determination of Regulatory Review Period 14 Feb, 2024 US9499545
transaction for FDA Determination of Regulatory Review Period 14 Feb, 2024 US8754096
Dispatch to FDC 09 Feb, 2024 US11925709
Application Is Considered Ready for Issue 09 Feb, 2024 US11925709
Issue Fee Payment Received 05 Feb, 2024 US11925709
Issue Fee Payment Verified 05 Feb, 2024 US11925709


Ubrogepant's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List